ArticlePloS one2026
Feasibility, acceptability, and preliminary efficacy of AdaptRehab VR, an immersive virtual reality system for upper limb stroke rehabilitation: A mixed-methods study in Ethiopia.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07412899 (AdaptRehab imVR), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
AdaptRehab imVR: Exploring the Feasibility of imVR for Upper Limb Stroke Rehabilitation in Ethiopia
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stroke is a leading cause of long-term disability, with a disproportionate burden in low- and middle-income countries (LMICs), where upper limb impairment emerges as one of its most prevalent and debilitating consequences. Upper limb impairment significantly limits independence and community participation, and this makes rehabilitation a critical priority. While conventional therapy is essential, its effectiveness is often limited by challenges in patient engagement and adherence. To address these barriers, immersive virtual reality (imVR) offers a promising modality for enhancing upper limb rehabilitation. This study examined the feasibility, acceptability, safety, and upper extremity outcomes of the AdaptRehab VR system in Ethiopia with the aim of informing future randomized controlled trials. A mixed-methods design was used, including quantitative assessments of upper extremity function, usability, user experience, and cybersickness, alongside qualitative interviews and focus group discussion (FGD). The study was conducted at Jimma University Teaching Hospital, Ethiopia, and enrolled 20 adults aged ≥18 years with subacute or chronic stroke. Eighteen participants completed nine AdaptRehab VR sessions over three weeks. Physiotherapists collected baseline and post-intervention data. In addition, 18 participants (interview) and 6 physiotherapists (FGD) provided qualitative feedback. The study followed CONSORT guidelines for pilot and feasibility studies. Feasibility was excellent, with 93% adherence. System Usability Scale scores indicated good usability (mean 76.2 ± 12.1). User Experience Questionnaire ratings were positive across attractiveness (1.92 ± 0.84), pragmatic quality (1.78 ± 0.79), and hedonic quality (1.84 ± 0.81). Cybersickness was minimal, with mild transient symptoms (sweating: n = 6; fatigue and headache: n = 3). Significant improvements were observed in the Action Research Arm Test (33.0 ± 13.2 to 48.6 ± 13.1, p < .001), and Box and Block Test (medians of 21.5 to 29, p < .001). Qualitative findings confirmed high acceptability, motivation, and perceived functional gains. The AdaptRehab VR system demonstrated strong feasibility, acceptability, and safety for upper limb stroke rehabilitation in Ethiopia. Positive user experiences and functional improvements support its potential in LMICs settings, warranting a fully powered randomized controlled trial.
trial registrationClinicalTrials.gov NCT07412899.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.